首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL23 |
| Uniprot No | P55773 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-120aa |
| 氨基酸序列 | RVTKDAETEF MMSKLPLENP VLLDRFHATS ADCCISYTPR SIPCSLLESY FETNSECSKP GVIFLTKKGR RFCANPSDKQ VQVCMRMLKL DTRIKTRKN |
| 预测分子量 | 11.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL23重组蛋白的参考文献示例(内容为概括性描述，非真实引用)：
1. **《Recombinant CCL23 induces monocyte migration via CCR1 activation》**
- 作者：Smith A, et al.
- 摘要：研究通过大肠杆菌系统成功表达并纯化重组CCL23蛋白，验证其通过CCR1受体介导单核细胞趋化迁移的功能，提示其在炎症反应中的作用。
2. **《Characterization of CCL23 isoforms and their roles in tumor-associated macrophage recruitment》**
- 作者：Lee J, et al.
- 摘要：分析CCL23两种重组蛋白异构体(CCL23α/β)的差异，发现CCL23β在肿瘤微环境中显著招募巨噬细胞，可能促进癌症进展。
3. **《Structural and functional analysis of CCL23 glycosylation variants》**
- 作者：Wang Y, et al.
- 摘要：通过哺乳动物表达系统制备糖基化修饰的重组CCL23.揭示糖链结构对其稳定性和趋化活性的调控作用。
4. **《CCL23 suppresses osteoclastogenesis in rheumatoid arthritis through a novel signaling pathway》**
- 作者：Kim T, et al.
- 摘要：研究发现重组CCL23蛋白可抑制破骨细胞分化，为类风湿性关节炎的骨破坏治疗提供潜在靶点。
**注**：以上为示例性内容，实际文献需通过PubMed、Web of Science等数据库检索。建议使用关键词“CCL23 recombinant protein”或“CCL23 chemokine function”查找近期研究。
CCL23 (C-C motif chemokine ligand 23), also known as MPIF-1 or Ckβ8-1. is a small secretory protein belonging to the CC chemokine family. It is encoded by the *CCL23* gene in humans and plays a role in immune regulation by recruiting leukocytes to sites of inflammation or infection. Structurally, CCL23 contains a conserved chemokine domain with four cysteine residues, forming two disulfide bonds critical for its three-dimensional structure and receptor-binding activity. It is produced as a precursor protein with a signal peptide, which is cleaved to release the mature, biologically active form.
Functionally, CCL23 primarily interacts with the CCR1 receptor expressed on monocytes, dendritic cells, T cells, and neutrophils. It mediates chemotaxis of these immune cells, facilitating their migration to inflammatory or damaged tissues. Studies suggest its involvement in chronic inflammatory diseases, autoimmune disorders, and cancer. In tumor microenvironments, CCL23 may exhibit dual roles: it can suppress anti-tumor immune responses by recruiting immunosuppressive cells, while also promoting angiogenesis and tumor cell proliferation in certain cancers.
Recombinant CCL23 is produced using genetic engineering techniques (e.g., bacterial or mammalian expression systems) and purified for research applications. It serves as a tool to study chemokine-receptor interactions, inflammatory pathways, and tumor immunology. Additionally, recombinant CCL23 has potential therapeutic implications, such as targeting CCR1 signaling to modulate immune responses in diseases like rheumatoid arthritis or metastatic cancers. Its expression levels in tissues or biofluids are also explored as biomarkers for disease progression. Despite its established roles, ongoing research aims to clarify its context-dependent mechanisms and therapeutic targeting strategies.
×
